Osimertinib Mesylate Tablets

DRUG9 trials

Sponsors

Sun Yat-sen University, Ascentage Pharma Group Inc., Shanghai JMT-Bio Inc., Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd.

Conditions

Advanced Non-small Cell Lung CancerAdvanced Solid TumorsEGFR Exon20 Insertion MutationsEGFR Positive Non-small Cell Lung CancerLocally Advanced or Metastatic Non-Small Cell Lung CancerNSCLC Patients With Brain MetastasisNon-small Cell Lung CancerRecurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression

Phase 1

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

Active, not recruitingNCT04001777

Ascentage Pharma Group Inc.EGFR Positive Non-small Cell Lung Cancer

Start: 2019-07-04End: 2026-06-30Target: 80Updated: 2025-10-01

VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer

Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.Advanced Non-small Cell Lung Cancer

Start: 2022-09-21End: 2024-04-24Target: 72Updated: 2023-06-15

Phase 2

Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer

Sun Yat-sen UniversityNon-small Cell Lung Cancer

Start: 2018-02-26End: 2020-12-31Target: 100Updated: 2018-03-09

Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

Shanghai JMT-Bio Inc.EGFR Exon20 Insertion Mutations, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Start: 2021-11-20End: 2024-09-30Target: 155Updated: 2021-11-24

A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Active, not recruitingNCT05880706

Sichuan Baili Pharmaceutical Co., Ltd.Non-small Cell Lung Cancer

Start: 2023-07-19End: 2027-07-31Updated: 2025-09-19

A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

RecruitingNCT06498986

Sichuan Baili Pharmaceutical Co., Ltd.Non-small Cell Lung Cancer

Start: 2024-07-31End: 2026-08-31Target: 40Updated: 2025-05-07

A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

RecruitingNCT06895928

Shanghai Hengrui Pharmaceutical Co., Ltd.Advanced Solid Tumors

Start: 2025-03-28End: 2028-12-31Target: 400Updated: 2025-04-22

Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

Not yet recruitingNCT06908772

Shanghai JMT-Bio Inc.Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression

Start: 2025-04-01End: 2030-01-31Target: 390Updated: 2025-04-03

Phase 3

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

RecruitingNCT06970639

Allist Pharmaceuticals, Inc.NSCLC Patients With Brain Metastasis

Start: 2024-09-26End: 2029-09-01Target: 380Updated: 2026-02-12

Related Papers

Phase I trial of aurora kinase A (AURKA) inhibitor VIC-1911 plus osimertinib for TKI-resistant, EGFR-mutant non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2024-06-015 citations

Preclinical Evaluation of JAB-2485, a Potent AURKA Inhibitor with High Selectivity and Favorable Pharmacokinetic Properties

ACS Omega2024-05-033 citations

137MO Phase II study of becotarug (JMT101) combined with osimertinib in patients (pts) with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion (ex20ins) mutations (BECOME study)

ESMO Open2024-03-013 citations

Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer

Nature Communications2023-06-1212 citations

Updated study results of pelcitoclax (APG-1252) in combination with osimertinib in patients (pts) with <i>EGFR</i>-mutant non–small cell lung cancer (NSCLC).

Journal of Clinical Oncology2022-06-011 citations